Return to Latest Recommendation
- Date of Publication: 10 May 2021
- Status: Assessment Complete
- Type of Health Technology: Drugs
- HTA Track: Expedited Track
- Topic Assignment: Internal Assessment Group
- Recommendation Status: Available
The HTA Council recommends the use of tocilizumab in addition to systemic steroids, in patients showing respiratory deterioration and/or requiring high doses of oxygen and with elevated markers of inflammation.
The HTA Council recommends against the use of tocilizumab among patients with COVID-19 infection who do not require oxygen supplementation. - Secretary of Health Decision Status: Available
- Evidence and Relevant Links: